Study #2023-0837
A Phase I/IIa theranostic study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPR-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617
MD Anderson Study Status
Enrolling
Treatment Agent
64Cu-SAR-BBN, 67Cu-SAR-BBN
Description
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostatic Neoplasms, Castration-Resistant
Study phase:
Physician name:
Amado Zurita-Saavedra
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-888-356-1897
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.